BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Imatinib is a selective tyrosine kinase inhibitor targeting the Philadelphia chromosome (BCR-ABL fusion oncoprotein) in CML, however, the drug also has action at several other tyrosine kinases, including platelet derived growth factor receptor (PDGFR) and c-abl [6].